(Q48659913)

14 February 2018

title

Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. (English)

1 reference

14 February 2018

0 references

0 references

0 references

Wami Marui

1

1 reference

14 February 2018

Eizo Iseki

2

1 reference

14 February 2018

Toshiki Nakai

3

1 reference

14 February 2018

Satoshi Miura

4

1 reference

14 February 2018

Masanori Kato

5

1 reference

14 February 2018

Kenji Uéda

6

1 reference

14 February 2018

Kenji Kosaka

7

1 reference

14 February 2018

publication date

1 March 2002

1 reference

14 February 2018

Journal of the Neurological Sciences

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

14 February 2018

volume

195

1 reference

14 February 2018

issue

2

1 reference

14 February 2018

page(s)

153-159

1 reference

14 February 2018

Diffuse Lewy body disease: clinical features in 15 cases

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Lewy bodies in cerebral cortex, report of three cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Parkinson's disease: Distribution of Lewy bodies and monoamine neuron system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: Light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Hippocampal pathology in diffuse Lewy body disease using ubiquitin immunohistochemistry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Accumulation of NACP/alpha-synuclein in lewy body disease and multiple system atrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Neuropathological stageing of Alzheimer-related changes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Identification of two distinct synucleins from human brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Alpha-synuclein in Lewy bodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Degenerative terminals of the perforant pathway are human alpha-synuclein-immunoreactive in the hippocampus of patients with diffuse Lewy body disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

A direct demonstration of the perforant pathway terminal zone in Alzheimer's disease using the monoclonal antibody Alz-50

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Degeneration process of Lewy bodies in the brains of patients with dementia with Lewy bodies using alpha-synuclein-immunohistochemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Glial involvement in the degeneration process of Lewy body-bearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

Occurrence of human alpha-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900006-0

10.1016/S0022-510X(02)00006-0

7 January 2021

Identifiers

DOI

1 reference

14 February 2018

PubMed ID

11897247

1 reference

14 February 2018